| Literature DB >> 32882989 |
Imam Fathoni1, Julie G Petitbois1, Walied M Alarif2, Ahmed Abdel-Lateff3,4, Sultan S Al-Lihaibi2, Erina Yoshimura5, Yasuyuki Nogata6, Charles S Vairappan7, Eti Nurwening Sholikhah8, Tatsufumi Okino1,9.
Abstract
Cyanobacteria are reported as rich sources of secondary metabolites that provide biological activities such as enzyme inhibition and cytotoxicity. Ten depsipeptide derivatives (lyngbyabellins) were isolated from a Malaysian Moorea bouillonii and a Red Sea Okeania sp.: lyngbyabellins G (1), O (2), P (3), H (4), A (7), 27-deoxylyngbyabellin A (5), and homohydroxydolabellin (6). This study indicated that lyngbyabellins displayed cytotoxicity, antimalarial, and antifouling activities. The isolated compounds were tested for cytotoxic effect against human breast cancer cells (MCF7), for antifouling activity against Amphibalanus amphitrite barnacle larvae, and for antiplasmodial effect towards Plasmodium falciparum. Lyngbyabellins A and G displayed potent antiplasmodial effect against Plasmodium, whereas homohydroxydolabellin showed moderate effect. For antifouling activity, the side chain decreases the activity slightly, but the essential feature is the acyclic structure. As previously reported, the acyclic lyngbyabellins are less cytotoxic than the corresponding cyclic ones, and the side chain increases cytotoxicity. This study revealed that lyngbyabellins, despite being cytotoxic agents as previously reported, also exhibit antimalarial and antifouling activities. The unique chemical structures and functionalities of lyngbyabellin play an essential role in their biological activities.Entities:
Keywords: Moorea; Okeania; antifouling; antiplasmodial; cyanobacteria; cytotoxic
Mesh:
Substances:
Year: 2020 PMID: 32882989 PMCID: PMC7504728 DOI: 10.3390/molecules25173986
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Structural diversity and antimalarial potential of secondary metabolites derived from cyanobacteria.
| Compounds | Sources | Structural Class | IC50 (µM) | Assay Method | References |
|---|---|---|---|---|---|
| Dolastatin 10 |
| peptide | 0.0001 | pLDH | [ |
| Dolastatin 15 | peptide | 0.0024 | pLDH | [ | |
| Gallinamide A | depsipeptide | 8.4 | Pico-Green | [ | |
| Hoshinoamide A |
| lipopeptides | 5.2 | pLDH | [ |
| Carmabin A |
| lipopeptides | 4.3 | Pico-Green | [ |
| Dragomabin |
| lipopeptides | 6.0 | Pico-Green | [ |
| Venturamide A | hexapeptides | 8.2 | Pico-Green | [ | |
| Companeramide A |
| depsipeptide | 5.7 | Sybr Green | [ |
| Mabunamide | lipopeptides | 1.4 | pLDH | [ | |
| Ikoamide | lipopeptides | 0.14 | pLDH | [ | |
| Kakeromamide B |
| pentapeptides | 8.9 | Sybr Green | [ |
| Ulongamide A |
| depsipeptides | 0.99 | Sybr Green | [ |
| Lyngbyabellin A |
| depsipeptides | 0.0015 | Sybr Green | [ |
| Bastimolide A |
| polyhydroxy macrolide | 0.27 | Sybr Green | [ |
| Bastimolide B |
| macrolide | 5.7 | Pico-Green | [ |
Figure 1Structure of depsipeptides isolated for this study: lyngbyabellin G (1), lyngbyabellin O (2), lyngbyabellin P (3), lyngbyabellin H (4), 27-deoxylyngbyabellin A, R = H (5), homohydroxydolabellin (6), and lyngbyabellin A, R = OH (7). Compounds 1–5 are from Okeania sp. and 6–7 from M. bouillonii.
Diversity of biological activities reported for Lyngbyabellins in the literature from 2000 to 2020.
| Compounds | Bioactivities | IC50 (µM) | EC50(µg/mL) | Cells Lines/Organisms | References |
|---|---|---|---|---|---|
| Lyngbyabellin A | Antimalarial, anticancer | 0.021–0.345 | HT29, HeLA, KB, LoVo | [ | |
| 0.0015 | |||||
| 0.3 | |||||
| 27-deoxylyngbyabellin A | Antifouling, anticancer | 0.0073–0.31 | HT29, HeLA, MCF7 | [ | |
| 0.09 (but toxic) | |||||
| Lyngbyabellin B | Anticancer | 0.1–1.1 | HT29, HeLA, CA46, PtK2 | [ | |
| Lyngbyabellin C | Anticancer | 2.1–5.3 | KB, LoVo | [ | |
| Lyngbyabellin D | Anticancer | 0.1 | KB | [ | |
| Lyngbyabellin E | Anticancer | 0.4–1.2 | H460, Neuro-2a | [ | |
| Lyngbyabellin F | Anticancer | 1.0–1.8 | H460, Neuro-2a | [ | |
| Lyngbyabellin G | Antimalarial, anticancer, antifouling | 2.2–120 | H460, Neuro-2a, MCF7 | [ | |
| 4.41 | |||||
| Lyngbyabellin H | Anticancer | 0.07–1.4 | H460, Neuro-2a, MCF7 | [ | |
| Inactive | [ | ||||
| Lyngbyabellin I | Anticancer | 0.7–1.0 | H460, Neuro-2a | [ | |
| Lyngbyabellin J | Anticancer | 0.041–0.054 | HT29, HeLA | [ | |
| Lyngbyabellin K | Inactive | H460 | [ | ||
| Lyngbyabellin L | Inactive | H460 | [ | ||
| Lyngbyabellin M | Inactive | H460 | [ | ||
| Lyngbyabellin N | Anticancer | 0.0048–1.8 | H460, HCT116 | [ | |
| Lyngbyabellin O | Antifouling | Inactive | MCF7 | [ | |
| 0.24 | |||||
| Lyngbyabellin P | Anticancer, antifouling | 9.0 | MCF7 | [ | |
| 0.62 |